Resources: Affiliate Scholarship
Coming together: Forging new paths to action for the Sustainable Development Goals
A partnership between the Center for Sustainable Development at Brookings and The Rockefeller Foundation, 17 Rooms is an experimental method for advancing the economic, social, and environmental priorities embedded in the…
Meaning in Lives Nearing Their End
In this paper, I consider the idea of meaning in life as I believe it has arisen in some discussions of ageing and death. I critically examine and compare the…
Responsible use of polygenic risk scores in the clinic: potential benefits, risks and gaps
Polygenic risk scores (PRSs) aggregate the many small effects of alleles across the human genome to estimate the risk of a disease or disease-related trait for an individual. The potential…
Read now! International Pandemic Lawmaking: Conceptual and Practical Issues Report
Between 20 September and 4 November 2021, the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School, Middlesex University London, and the Max Planck Institute of Comparative Public Law…
Simplify drug labelling to show benefits clearly
Aducanumab, an Alzheimer’s disease treatment, was approved by the US Food and Drug Administration (FDA) in June this year despite a lack of robust evidence that it actually…
From health to political economy: How we ‘know what we know’ and why intersecting matters now
That our world is growingly complex is hardly a radical revelation. The challenge is to act accordingly. To widen our knowledge, we specialize and consequently isolate ourselves in various silos.…
Human Rights Obligations of States to not impede the Proposed COVID-19 TRIPS Waive
This opinion applies to the full range of diagnostics, medications, vaccines, therapeutics and other relevant health products required for the containment, prevention and mitigation of COVID-19. In short, it sets…
Understanding The New Drug Price Reform Deal
Yesterday, the text of the Democratic deal on prescription drug pricing reform was released. These drug pricing reforms are intended to move forward as part of a broader reconciliation package…
Editorial: Can a Pandemic Law-Making Exercise Promote Global Health Justice?
Amid the unfolding "moral catastrophe" of COVID-19, and across the entries in this symposium, we see a clamor for any pandemic law-making exercise to promote more justice in…
Problematic Interactions Between AI and Health Privacy
The interaction of artificial intelligence (AI) and health privacy is a two-way street. Both directions are problematic. This Essay makes two main points. First, the advent of artificial intelligence weakens…
Diagnóstico de la participación de las mujeres en el sistema de justicia argentino
En Argentina, la Constitución Nacional recoge la cláusula general de igualdad, pero no incorpora un principio de representación paritaria. Sin embargo, a partir de…
Integrating Supported Decision-Making into the Clinical Research Process
Peterson, Karlawish, and Largent’s (2021) “Supported Decision Making with People at the Margins of Autonomy” brings welcome attention to the rights of people with cognitive impairment and…
Cross-Border Transfers of Personal Data after Schrems II: Supplementary Measures and New Standard Contractual Clauses (SCCs)
This article analyses the legal challenges of international data transfers resulting from the recent Court of Justice of the European Union (CJEU) decision in Case C-311/18 Data Protection Commissioner v…
FDA Drug Approval and the Ethics of Desperation
In justifying the accelerated approval of aducanumab (Aduhelm; Biogen), US Food and Drug Administration (FDA) officials emphasized that many patients with Alzheimer disease and their families “made it clear…
Steps toward a System of IRB Precedent: Piloting Approaches to Summarizing IRB Decisions for Future Use
Institutional review boards (IRBs) have been criticized for inconsistency and lack of transparency in decision-making, problems that undermine both trust in their ability to protect human research participants and respect…
German Pharmaceutical Pricing: Lessons for the United States
To control pharmaceutical spending and improve access, the United States could adopt strategies similar to those introduced in Germany by the 2011 German Pharmaceutical Market Reorganization Act. In Germany, manufacturers sell…
When Should Neuroendovascular Care for Patients With Acute Stroke Be Palliative?
Noncurative surgeries intended to relieve suffering during serious illness or near end of life have been analyzed across palliative settings. Yet sparse guidance is available to inform clinical management decisions…
Helpful Lessons and Cautionary Tales: How Should COVID-19 Drug Development and Access Inform Approaches to Non-Pandemic Diseases?
After witnessing extraordinary scientific and regulatory efforts to speed development of and access to new COVID-19 interventions, patients facing other serious diseases have begun to ask “where’s…
Telehealth to Address Health Disparities: Potential, Pitfalls, and Paths Ahead
Telehealth has the potential to address health disparities, but not without deliberate choices about how to implement it. To support vulnerable patients, health policy leaders must pursue creative solutions such…
Pharmaceutical Companies, Human Rights, and the Alien Tort Statute
On January 3, 2019, U.S. District Judge Theodore D. Chuang of the U.S. District Court of the District of Maryland took a crucial first step in redressing one of the…